Neogen Corporation · NASDAQ:NEOG
Neogen — Q4 2025 Earnings Presentation
13 slides from Neogen's earnings presentation, Jul 29, 2025
Slide 1: Fiscal Year 2025 Fourth-Quarter Results
Fiscal Year 2025 Fourth-Quarter Results July 29, 2025 ©2020 NEOGEN Corporation. All rights reserved.
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation includes “forward-looking statements” as that term is defined in Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Neogen’s curr
Slide 3: Q4 FY25 Summary
Q4 FY25 Summary • Continued to manage through soft end-market environment ‒ Food production volumes generally remained down and worsened sequentially • LSD Food Safety core growth outside of sample collection product line ‒ Petrifilm integration progressing on track – comprehensive costing analysis
Slide 4: Targeted Improvement Plan
Targeted Improvement Plan Priority Improvement Actions Growth Acceleration and Margin Expansion Accelerate Food Safety growth to consistently above-market rates (MSD+ long-term market growth rate) ‒ Drive share gains in North America – return to growth rates of MSD or above ‒ Continued internation
Slide 5: Financial Highlights
Financial Highlights Adjusted Net Income(3) Revenue ($M) Adjusted EBITDA ($M) (2) ($M, excl. per share) $236.8 $225.5 $53.0 $40.6 $22.4 $0.10 $11.3 22.4% Adjusted 18.0% $0.05 Margin EPS (3) Margin Adjusted (3) EPS Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 • Core revenue growth(1) of (1.3)% in
Slide 6: Balance Sheet & Capital Allocation
Balance Sheet & Capital Allocation Debt Profile • Q4 Free Cash Flow(2) improved by $14M compared to Q3 Gross Debt $900M Gross Debt – Driven primarily by trade working capital, lower capex and Less: Cash & no required interest payment on senior notes $800M Equivalents $129M Less: Cash & Equivalents $
Slide 7: FY26 Outlook
FY26 Outlook • Initiating full-year outlook – Includes 6 weeks of results for divested Cleaners & Disinfectants business • Revenue: $820 – $840 million – Reflects continuation of soft macro environment, improvement from H2 FY25 sample collection run rate, slower China • Adjusted EBITDA: $165 – $175
Slide 8: Summary
Summary ‒ Making progress against key priorities laid out in targeted improvement plan ‒ Navigating end-market weakness and global trade uncertainty ‒ Actions underway to address sample collection profitability and inventory challenges ‒ New Petrifilm plant on track – focused on project governance a
Slide 9: Thank you for joining us.
To view the earnings press release Thank you for and presentation, visit: WWW.NEOGEN.COM/INVESTOR-RELATIONS joining us. 9 ©2024 NEOGEN Corporation. All rights reserved.
Slide 10: Appendix
Appendix
Slide 11: Non-GAAP Reconciliations: Adjusted EBITDA
Non-GAAP Reconciliations Adjusted EBITDA 11 ©2024 NEOGEN Corporation. All rights reserved.
Slide 12: Non-GAAP Reconciliations: Adjusted Net Income
Non-GAAP Reconciliations Adjusted Net Income 12 ©2024 NEOGEN Corporation. All rights reserved.
Slide 13: Non-GAAP Reconciliations: Core Growth and Free Cash Flow
Non-GAAP Reconciliations Core Growth and Free Cash Flow 13 ©2024 NEOGEN Corporation. All rights reserved.